Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed severe preeclampsia diagnosed prior to delivery~   Preeclampsia defined as: Blood pressure \> 140/90 AND proteinuria \> 300mg/24 hours OR 2+ on repeat dip stick~   Severe Preeclampsia defined as the presence of one or more of the following:~   i. systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 110 mmHg on 2 occasions at least 4 hours apart~   ii. new-onset cerebral or visual disturbance~   iii. severe persistent right upper quadrant pain or serum transaminase concentrations ≥ 2 times the upper limit of normal~   iv. thrombocytopenia (platelets \< 100 x 109/L)~   v. renal insufficiency (serum creatinine \> 97.2 umol/L)~   vi. pulmonary edema~2. A singleton gestation~3. Gestation between 24+0/7 to 40+6/7 weeks.Exclusion Criteria:~Exclusion Criteria:~1. Multiple pregnancy~2. Chronic hypertension or other condition requiring the use of BP-lowering medication~3. Cardiovascular disorders: Unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure~4. Known allergy or sensitivity to aspirin used in the study~5. Any medical comorbidity that is a contraindication to LD-ASA: Hemophilia or other bleeding disorder, history of GI bleeding, renal failure, severe liver disease, thrombocytopenia, gout, G6PD deficiency~6. Recent history of drug/alcohol abuse (\< 1 year prior to delivery), or receiving treatment for such~7. Nasal polyps~8. Hypercholesterolemia requiring pharmaceutical treatment~9. Raynaud's phenomenon~10. Collagen-vascular disease: lupus, scleroderma, rheumatoid arthritis~11. History of pre-existing diabetes~12. Ongoing use of any of the following medications: methotrexate, anti-coagulants, thrombolytics, oral hypoglycemics, uricsuric agents, valproic acid, glucocorticosteroids, digoxin

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PO LD-ASA (Type: EXPERIMENTAL): Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
- PO Placebo (Type: PLACEBO_COMPARATOR): A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).